Sickle cell disease: A neglected chronic disease of increasing global health importance

Archives of Disease in Childhood

Volumn 100, Issue 1, 2015, Pages 48-53

  Chakravorty, Subarna ^a   Williams, Thomas N ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

HAEMOPHILUS VACCINE; HEMOGLOBIN S; HYDROXYUREA; LEAD; PNEUMOCOCCUS VACCINE; VANILLOID RECEPTOR 1;

ABDOMINAL PAIN; ACUTE CHEST SYNDROME; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIBIOTIC PROPHYLAXIS; ARTICLE; ASPLENIA; AVASCULAR NECROSIS; BLOOD TRANSFUSION; BONE MARROW NECROSIS; CHILDHOOD; CLINICAL FEATURE; COMMUNITY ACQUIRED PNEUMONIA; CONVALESCENCE; DISEASE FREE SURVIVAL; EARLY INTERVENTION; FAT EMBOLISM; FOLLOW UP; GENE MUTATION; GENE THERAPY; GIRDLE SYNDROME; GLOBIN GENE; HEALTH PROGRAM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HETEROZYGOTE; HUMAN; ILEUS; INCOME; ISCHEMIC COLITIS; LIFE EXPECTANCY; MALARIA; NEUROPATHIC PAIN; NEWBORN SCREENING; OCCLUSION; PATHOPHYSIOLOGY; POPULATION MIGRATION; PRIAPISM; PROTEIN ELECTROPHORESIS; SEPSIS; SICKLE CELL ANEMIA; STANDARD; TRICUSPID VALVE DISEASE; VACCINATION; CHILD; CHRONIC DISEASE; HEALTH; NEGLECTED DISEASE; NEWBORN; PRESCHOOL CHILD; PROCEDURES;

ANEMIA, SICKLE CELL; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; GLOBAL HEALTH; HUMANS; INFANT, NEWBORN; NEGLECTED DISEASES; NEONATAL SCREENING;

EID: 84919344025     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/archdischild-2013-303773     Document Type: Article

References (86)

1. Murayama M. Structure of sickle cell hemoglobin and molecular mechanism of the sickling phenomenon. Clin Chem 1967;13:578-88.
2. Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ 2008;86:480-7.
3. Nagel RL, Fabry ME, Steinberg MH. The paradox of hemoglobin SC disease. Blood Rev 2003;17:167-78.
4. Serjeant GR, Serjeant BE, Fraser RA, et al. Hb S-beta-thalassemia: molecular, hematological and clinical comparisons. Hemoglobin 2011;35:1-12.
5. Herrick JB. Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia. 1910. Yale J Biol Med 2001;74:179-84.
6. Pauling L, Itano HA, Singer SJ, et al. Sickle cell anemia a molecular disease. Science 1949;110:543-8.
7. Ingram VM. A specific chemical difference between the globins of normal human and sickle-cell anaemia haemoglobin. Nature 1956;178:792-4.
8. Conner BJ, Reyes AA, Morin C, et al. Detection of sickle cell beta S-globin allele by hybridization with synthetic oligonucleotides. Proc Natl Acad Sci USA 1983;80:278-82.
9. Kan YW, Dozy AM, Alter BP, et al. Detection of the sickle gene in the human fetus. Potential for intrauterine diagnosis of sickle-cell anemia. N Engl J Med 1972;287:1-5.
10. JV D. The haemolytic anaemias-congential and acquired. New York: Grune and Stratton, 1960.
11. Scott RB. Health care priority and sickle cell anemia. JAMA 1970;214:731-4.
12. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994;330:1639-44.
13. Leikin SL, Gallagher D, Kinney TR, et al. Mortality in children and adolescents with sickle cell disease. Cooperative Study of Sickle Cell Disease. Pediatrics 1989;84:500-8.
14. Quinn CT, Rogers ZR, Buchanan GR. Survival of children with sickle cell disease. Blood 2004;103:4023-7.
15. Wierenga KJ, Hambleton IR, Lewis NA. Survival estimates for patients with homozygous sickle-cell disease in Jamaica: a clinic-based population study. Lancet 2001;357:680-3.
16. Telfer P, Coen P, Chakravorty S, et al. Clinical outcomes in children with sickle cell disease living in England: a neonatal cohort in East London. Haematologica 2007;92:905-12.
17. Quinn CT, Rogers ZR, McCavit TL, et al. Improved survival of children and adolescents with sickle cell disease. Blood 2010;115:3447-52.
18. Hamideh D, Alvarez O. Sickle Cell Disease Related Mortality in the United States (1999-2009). Pediatr Blood Cancer 2013;60:1482-6.
19. Allison AC. Protection afforded by sickle-cell trait against subtertian malareal infection. Br Med J 1954;1:290-4.
20. Taylor SM, Cerami C, Fairhurst RM. Hemoglobinopathies: slicing the Gordian knot of Plasmodium falciparum malaria pathogenesis. PLoS Pathog 2013;9:e1003327.
21. Piel FB, Patil AP, Howes RE, et al. Global distribution of the sickle cell gene and geographical confirmation of the malaria hypothesis. Nat Commun 2010;1:104.
22. Grosse SD, Odame I, Atrash HK, et al. Sickle cell disease in Africa: a neglected cause of early childhood mortality. Am J Prev Med 2011;41:S398-405.
23. Piel FB, Tatem AJ, Huang Z, et al. Global migration and the changing distribution of sickle haemoglobin: a quantitative study of temporal trends between 1960 and 2000. Lancet Glob Health 2014;2:e80-9.
24. Piel FB, Patil AP, Howes RE, et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet 2013;381:142-51.
25. Williams TN, Uyoga S, Macharia A, et al. Bacteraemia in Kenyan children with sickle-cell anaemia: a retrospective cohort and case-control study. Lancet 2009;374:1364-70.
26. McAuley CF, Webb C, Makani J, et al. High mortality from Plasmodium falciparum malaria in children living with sickle cell anemia on the coast of Kenya. Blood 2010;116:1663-8.
27. Ndila C, Bauni E, Nyirongo V, et al. Verbal autopsy as a tool for identifying children dying of sickle cell disease: a validation study conducted in Kilifi district, Kenya. BMC Med 2014;12:65.
28. Ryan K, Bain BJ, Worthington D, et al. Significant haemoglobinopathies: guidelines for screening and diagnosis. Br J Haematol 2010;149:35-49.
29. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet 2010;376:2018-31.
30. Ataga KI, Moore CG, Hillery CA, et al. Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension. Haematologica 2008;93:20-6.
31. Kato GJ, McGowan V, Machado RF, et al. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood 2006;107:2279-85.
32. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004;350:886-95.
33. Kato GJ, Hsieh M, Machado R, et al. Cerebrovascular disease associated with sickle cell pulmonary hypertension. Am J Hematol 2006;81:503-10.
34. Sun K, Xia Y. New insights into sickle cell disease: a disease of hypoxia. Curr Opin Hematol 2013;20:215-21.
35. Ballas SK, Gupta K, Adams-Graves P. Sickle cell pain: a critical reappraisal. Blood 2012;120:3647-56.
36. Hillery CA, Kerstein PC, Vilceanu D, et al. Transient receptor potential vanilloid 1 mediates pain in mice with severe sickle cell disease. Blood 2011;118:3376-83.
37. Berger E, Saunders N, Wang L, et al. Sickle cell disease in children: differentiating osteomyelitis from vaso-occlusive crisis. Arch Pediatr Adolesc Med 2009;163: 251-5.
38. Almeida A, Roberts I. Bone involvement in sickle cell disease. Br J Haematol 2005;129:482-90.
39. Mahadeo KM, Oyeku S, Taragin B, et al. Increased prevalence of osteonecrosis of the femoral head in children and adolescents with sickle-cell disease. Am J Hematol 2011;86:806-8.
40. Milner PF, Kraus AP, Sebes JI, et al. Sickle cell disease as a cause of osteonecrosis of the femoral head. N Engl J Med 1991;325:1476-81.
41. Adekile AD, Gupta R, Yacoub F, et al. Avascular necrosis of the hip in children with sickle cell disease and high Hb F: magnetic resonance imaging findings and influence of alpha-thalassemia trait. Acta Haematol 2001;105:27-31.
42. Burnett MW, Bass JW, Cook BA. Etiology of osteomyelitis complicating sickle cell disease. Pediatrics 1998;101:296-7.
43. Neonato MG, Guilloud-Bataille M, Beauvais P, et al. Acute clinical events in 299 homozygous sickle cell patients living in France. French Study Group on Sickle Cell Disease. Eur J Haematol 2000;65:155-64.
44. Miller AC, Gladwin MT. Pulmonary complications of sickle cell disease. Am J Respir Crit Care Med 2012;185:1154-65.
45. Boyd JH, Macklin EA, Strunk RC, et al. Asthma is associated with acute chest syndrome and pain in children with sickle cell anemia. Blood 2006;108:2923-7.
46. Paul R, Minniti CP, Nouraie M, et al. Clinical correlates of acute pulmonary events in children and adolescents with sickle cell disease. Eur J Haematol 2013;91:62-8.
47. Gordeuk VR, Minniti CP, Nouraie M, et al. Elevated tricuspid regurgitation velocity and decline in exercise capacity over 22 months of follow up in children and adolescents with sickle cell anemia. Haematologica 2011;96:33-40.
48. Pearson HA, Spencer RP, Cornelius EA. Functional asplenia in sickle-cell anemia. N Engl J Med 1969;281:923-6.
49. William BM, Thawani N, Sae-Tia S, et al. Hyposplenism: a comprehensive review. Part II: clinical manifestations, diagnosis, and management. Hematology 2007;12:89-98.
50. Luzzatto L. Sickle cell anaemia and malaria. Mediterr J Hematol Infect Dis 2012;4: e2012065.
51. Booth C, Inusa B, Obaro SK. Infection in sickle cell disease: a review. Int J Infect Dis 2010;14:e2-12.
52. Ellison AM, Ota KV, McGowan KL, et al. Epidemiology of Bloodstream Infections in Children with Sickle Cell Disease. Pediatr Infect Dis J 2013;32:560-3.
53. Topley JM, Rogers DW, Stevens MC, et al. Acute splenic sequestration and hypersplenism in the first five years in homozygous sickle cell disease. Arch Dis Child 1981;56:765-9.
54. Brousse V, Buffet P, Rees D. The spleen and sickle cell disease: the sick(led) spleen. Br J Haematol 2014;166:165-76.
55. Emond AM, Collis R, Darvill D, et al. Acute splenic sequestration in homozygous sickle cell disease: natural history and management. J Pediatr 1985;107:201-6.
56. Norris WE. Acute hepatic sequestration in sickle cell disease. J Natl Med Assoc 2004;96:1235-9.
57. Gardner K, Suddle A, Kane P, et al. How we treat sickle hepatopathy and liver transplantation in adults. Blood 2014;123:2302-7.
58. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 1998;91:288-94.
59. Musallam KM, Khoury RA, Abboud MR. Cerebral infarction in children with sickle cell disease: a concise overview. Hemoglobin 2011;35:618-24.
60. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998;339:5-11.
61. Adams RJ, Brambilla D, Optimizing Primary Stroke Prevention in Sickle Cell Anemia Trial I. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med 2005;353:2769-78.
62. Ware RE, Helms RW, Investigators SW. Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood 2012;119:3925-32.
63. DeBaun MR, Gordon M, McKinstry RC, et al. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med 2014;371:699-710.
64. DeBaun MR, Armstrong FD, McKinstry RC, et al. Silent cerebral infarcts: a review on a prevalent and progressive cause of neurologic injury in sickle cell anemia. Blood 2012;119:4587-96.
65. Qureshi A, Lang N, Bevan DH. Sickle cell 'girdle syndrome' progressing to ischaemic colitis and colonic perforation. Clin Lab Haematol 2006;28:60-2.
66. Donaldson JF, Rees RW, Steinbrecher HA. Priapism in children: a comprehensive review and clinical guideline. J Pediatr Urol 2014;10:11-24.
67. Burnett AL, Anele UA, Trueheart IN, et al. Randomized controlled trial of sildenafil for preventing recurrent ischemic priapism in sickle cell disease. Am J Med 2014;127:664-8.
68. Lucas SB, Mason DG. A Sickle Crisis? In: Mason M, ed. UK: National Confidential Enquiry into Patient Outcome and Death, 2008.
69. Streetly A, Latinovic R, Hall K, et al. Implementation of universal newborn bloodspot screening for sickle cell disease and other clinically significant haemoglobinopathies in England: screening results for 2005-7. J Clin Pathol 2009;62:26-30.
70. Dick M. Sickle cell disease in childhood-standards and guidelines for clinical care, 2010. http://sct.screening.nhs.uk/standardsandguidelines
71. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995;332:1317-22.
72. Kinney TR, Helms RW, O'Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood 1999;94:1550-4.
73. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet 2011;377:1663-72.
74. Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. Am J Hematol 2010;85:403-8.
75. Brandow AM, Jirovec DL, Panepinto JA. Hydroxyurea in children with sickle cell disease: practice patterns and barriers to utilization. Am J Hematol 2010;85:611-13.
76. Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med 2000;342:1855-65.
77. Miller ST, Wright E, Abboud M, et al. Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia. J Pediatr 2001;139:785-9.
78. Alvarez O, Yovetich NA, Scott JP, et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. Am J Hematol 2013;88:932-8.
79. Chou ST. Transfusion therapy for sickle cell disease: a balancing act. Hematol Am Soc Hematol Educ Program 2013;2013:439-46.
80. Wayne AS, Schoenike SE, Pegelow CH. Financial analysis of chronic transfusion for stroke prevention in sickle cell disease. Blood 2000;96:2369-72.
81. Wang WC, Oyeku SO, Luo Z, et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics 2013;132:677-83.
82. Locatelli F, Pagliara D. Allogeneic hematopoietic stem cell transplantation in children with sickle cell disease. Pediatr Blood Cancer 2012;59:372-6.
83. Dallas MH, Triplett B, Shook DR, et al. Long-term outcome and evaluation of organ function in pediatric patients undergoing haploidentical and matched related hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant 2013;19:820-30.
84. Dong A, Rivella S, Breda L. Gene therapy for hemoglobinopathies: progress and challenges. Transl Res 2013;161:293-306.
85. Chandrakasan S, Malik P. Gene therapy for hemoglobinopathies: the state of the field and the future. Hematol Oncol Clin North Am 2014;28:199-216.
86. Hoots WK, Shurin SB. Future directions of sickle cell disease research: the NIH perspective. Pediatr Blood Cancer 2012;59:353-7.